1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Can UCB's Bimekizumab Go From Last To First In Psoriasis?

Skin Clearance Data Tops Rivals

 
• By Kevin Grogan

Although it is playing catching up on well-established rivals, especially Novartis's Cosentyx, the Belgian company believes that bimekizumab provides both a fast and durable response for psoriasis patients, driven by impressive PASI 100 rates.

Racing
UCB hopes bimekizumab can overtake Cosentyx for psoriasis • Source: Shutterstock

UCB Group may be late to the party when it comes to innovative psoriasis biologics but the latest sets of skin clearance data presented on its investigational IL-17A and IL-17F inhibitor bimekizumab suggest that the Belgian group's therapy could prove to be superior to rivals, not least Novartis AG's big-earning Cosentyx.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.

Equillium Seeks Accelerated Approval For GVHD Drug Despite Primary Endpoint Miss

 
• By Alaric DeArment

The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

More from Therapy Areas

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Multiple Tactics Likely Needed To Control Obesity Drug Costs

 
• By Alaric DeArment

ICER’s new white paper pointed to estimates that the GLP-1 drugs may result in more than $100bn in annual spending, highlighting the need to rein in costs.

Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind

 
• By Alaric DeArment

The company announced positive Phase IIb data for Descartes-08 in myasthenia gravis, with especially strong efficacy among patients without prior biologic treatment.